Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing transformative medicines for people with serious diseases. The company has four approved product franchises: CFTR modulators (TRIKAFTA/KAFTRIO and ALYFTREK) for cystic fibrosis, which treat approximately 95% of all people living with CF across more than 60 countries; CASGEVY, a CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia approved in 39 countries; and JOURNAVX (suzetrigine), a first-in-class, non-opioid NaV1.8 pain signal inhibitor for moderate-to-severe acute pain. Vertex is pursuing diversification into nephrology with povetacicept (a dual BAFF/APRIL inhibitor) for IgA nephropathy and other B cell-mediated diseases, inaxaplin for APOL1-mediated kidney disease, VX-407 for autosomal dominant polycystic kidney disease, stem cell-derived islet cell therapies for type 1 diabetes, and VX-670 for myotonic dystrophy type 1. The company has entered into a definitive agreement to acquire Crinetics Pharmaceuticals, which would add rare endocrine diseases as a fifth therapeutic pillar. Vertex trades on Nasdaq under the ticker VRTX. Updated Aug 3, 2026